Xencor initiated with a Buy at BTIG. BTIG analyst Dane Leone started Xencor with a Buy rating and $56 price target. The analyst is optimistic for the use of XmAb5871 in the treatment of systemic lupus erythematosus into the Phase 2 read-out during the second half of 2018. Further, he believes the commercialization of Xencor’s partner assets, ALXN1210 and MOR208, should help support its cash flow for the next several years.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.